• Sol-gel nose-to-brain system offers superior drug delivery
• New extraction protocol makes accurate and precise quantification of cannabinoids possible
• Establishment of cannabis division to commercialize research developments

A recent release from PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) shows that, in cannabinoid extraction technology, the health sciences company is getting it right. The company announced that, during its soluble gel drug delivery research and development program – the Sol-gel Program – it had successfully optimized the conditions for extracting cannabinoids from one of its cannabis strains and developed a proprietary method – the Extraction Protocol – for the accurate and precise quantification of cannabinoids present in the extract (http://ibn.fm/iKOST). This technological triumph will allow PRVCF to generate a range of cannabinoid-based Sol-gel formulations, each with a distinct, well-defined composition profile, based on specifications from clinical trial data that determine efficacy and safety. PRVCF is expecting that its drug delivery Sol-gel system will be employed in a range of therapeutic applications that target, initially, anxiety, cachexia, chemotherapy-induced nausea and pain.

The accuracy and precision of PreveCeutical’s Extraction Protocol has been checked against eight commercial cannabinoid standards over a broad concentration range. Its validation means that it can now be directly applied to the four other cannabis strains used in the Sol-gel program. The Extraction Protocol will expedite the creation of a library of chemically fingerprinted cannabinoid extracts, each with a complementary cannabinoid composition. These unique extracts will be optimized and integrated with the Sol-gel technology for use in a variety of therapeutic applications.

To complement the sophistication of its extraction and formulation methodologies, PreveCeutical is in search of hardware for its cannabinoid Sol-gel technology. As Dr. Harry Parekh explained in a recent interview, CBD Sol-gel is a nose-to-brain delivery system and so optimizing the “spray profile” is just as important as getting the formulation right (http://ibn.fm/nsv1l). Formulation and spray profiles go “hand in hand.” PRVCF has been working very closely with the global leader in spray device manufacture, a company based in Europe, in a quest for the optimal applicator. PreveCeutical has now narrowed its choice to two devices that appear to be “optimal for the delivery of the cannabinoid sol-gels into the nasal cavity.”

Most nasal application methods require “upwards of one or two dozen sprays, every twenty-hour hours, which is effectively the patient drinking it, post-nasally.” However, PRVCF believes that its approach will have the edge, because its spray will gel as soon as it hits the nasal mucosa, avoiding any post-nasal swallowing, and, therefore, one-to-three applications per week may be all that is required.

The Sol-gel system is an innovative nose-to-brain drug delivery platform that holds the promise of making medication regimens more effective. When therapeutic compounds are taken orally (many are), they travel through the stomach and intestines and are metabolized, which reduces their effectiveness. However, the Sol-gel system works by nasal administration and delivers the therapeutic agent to the mucosal tissue lining the nostrils, where it is transmitted rapidly to the brain, increasing bioavailability. Additionally, the gel stays in the nasal passages, slowly releasing the CBD while keeping it active for up to seven days. This ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.

PreveCeutical has established a cannabis division to commercialize its advances with the cannabinoid Sol-gel technology (http://ibn.fm/5SRGc).

“Given the progress we have made with the extractions and the refined formulations… we believe they can now be channeled into multiple different dosage forms – wafers, tablets, or sprays – so there’s a whole range of different applications that we can put the base technology into for a range of different clinical applications,” Parekh stated in a news release.

For the millions who suffer from anxiety, cachexia, chemotherapy-induced nausea and pain, this is good news. Clinical trials are expected to begin by the end of 2019.

For more information, visit the company’s website at www.PreveCeutical.com

• The first products resulting from the joint venture between Cannabis Strategic Ventures and True Promise Beauty are scheduled to be launched by the end of 2018
• The CBD-based luxury cosmetics line will feature face, skin and hair care products
• These products feature innovative formulations that aren’t currently available; the two companies hope to achieve strategic success in a constantly expanding luxury skin care market

Cannabis Strategic Ventures, Inc. (OTC: NUGS) and True Promise Beauty have announced the development of LYXR – a new line of cannabidiol (CBD)-based luxury skin and hair care products. The entire LYXR line will be developed from ingredients like hemp-derived phytocannabinoids and other natural components, according to a company announcement on September 20, 2018 (http://ibn.fm/KSKKD).

Cannabis Strategic Ventures and True Promise Beauty will first launch a face mask that is made from a CBD isolate. The applications of CBD in the cosmetic industry are numerous. Cannabidiol is believed to have anti-aging hydrating properties, as well as anti-inflammatory and antioxidant effects. Upon the full development of the LYXR range, the line will feature face, hair and skin care products. According to an official announcement, LYXR products will become available for purchase in early winter 2018.

The news came as a week earlier, on September 13, 2018, Cannabis Strategic Ventures and True Promise Beauty announced a strategic partnership aimed at the development of innovative skincare products. Under the terms and conditions of the agreement, Cannabis Strategic Venture acquired access to a proprietary hemp-derived CBD-infused formula developed by True Promise Beauty. In addition, the company gained access to well-established distribution channels (http://ibn.fm/i0Ywi).

Cannabis Strategic Ventures CEO Simon Yu said in a news release that LYXR provides an amazing opportunity for the introduction of cannabis science in the world of luxury cosmetic products. According to True Promise Beauty President Gail Johnson, the partnership will create a product line that’s brand new to the marketplace. CBD, combined with viable cosmetic formulas developed by experienced chemists, could potentially revolutionize the topical approach to skincare, haircare and body care, Johnson said.

A 2017 report suggests that the global personal care product market is bound to grow to $650.1 billion by 2024 (http://ibn.fm/QYIwv). The face mask market alone is forecast to register an increase of $8 billion by 2020.

LYXR’s initial distribution will target existing distribution networks in the U.S. Product developers believe that the scientifically-proven benefits of CBD will enable cosmetics developers to enter a new era marked by innovative proprietary formulas.

Based in Los Angeles, California, Cannabis Strategic Ventures focuses on supporting entrepreneurial growth within the legal cannabis industry. The company has a selective portfolio of subsidiaries aimed at offering outsourced personnel solutions that are tailor-made to address the needs of various companies specializing in the sector, including cultivators, dispensaries, manufacturers and other cannabis market areas.

True Promise Beauty was founded by Gail Johnson, an Emmy-nominated makeup artist. Johnson’s primary aim was to develop high quality products that even actors and actresses could use to get instantaneous skin rejuvenation. The company has well-established distribution channels with companies such as L’Oréal (OTC: LRLCY), Beauty Systems Group and Salon Centric.

For more information, visit the company’s website at www.CannabisStrategic.com

• The spread of digital devices is promoting omni-channel marketing
• Customers want the convenience of paying any which way
• NETE platforms handle over 100 different payment options in over 40 currencies
• Company intends to launch subscription-based payment processing with Payment Club, Inc.

The days when retailers waited hopefully for customers to visit their High Street locations are long gone. In this digital age, consumers are pursued and wooed wherever they congregate, which could be a news site, an online forum or a social media platform. They may be using a desktop, a tablet, or, very likely, a smartphone – different devices that require different configurations for accepting payments. As a result, the retailer whose shopping cart can only accept orders from one of these will be missing out, while his savvy competitor, using a service from Net Element, Inc. (NASDAQ: NETE), offers a smooth, seamless shopping experience to customers. Net Element is a global fintech provider with technology that facilitates acceptance of electronic payments in an omni-channel environment.

Our shopping expeditions are decidedly different from those undertaken by Mom and Pop. Research by Google (http://ibn.fm/6bIu4) reveals “that consumers want more information and customized experiences during their shopping journey: Two in three shoppers who tried to find information within a store say they didn’t find what they needed, and 43% of them left frustrated. And 71% of in-store shoppers who use smartphones for online research say their device has become more important to their in-store experience.”

The evolution and spread of digital devices has fundamentally altered our approach to commerce. Importantly, consumers now rely on their PCs and smartphones to “window shop” products. After this initial research, actual sales may be realized in a variety of ways.

Regardless of the channel, Net Element has a platform to handle it. The solutions offered by the company enable merchants of all sizes to accept and process over 100 different payment options in more than 40 currencies, including credit, debit and prepaid payments. Net Element also provides merchants with value-added services and technologies, including integrated payment technologies, point-of-sale solutions, security solutions, fraud management, information solutions and analytical tools.

Net Element owns and operates the following subsidiaries:

• Digital Provider – A leading provider of SMS messaging and mobile billing solutions
• Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology
• PayOnline – A fully integrated, processor-agnostic electronic commerce platform
• Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012

Recently, Net Element announced that its Unified Payments division had, through its partnership with an institutional investor, arranged a $5 million credit facility for Payment Club to drive its growth initiatives (http://ibn.fm/5N6JC). Unified Payments will soon be launching subscription-based payment processing services through the alliance with Payment Club, Inc., expanding its services in cashless payment acceptance.

For more information, visit the company’s website at www.NetElement.com

• Company’s MIDS Cardiac device aims to help ER personnel perform quick, high-sensitivity analysis of heart events
• MIDS device’s handheld portability is being developed to allow quick-response resource to minimally trained ambulance personnel
• Final device could ultimately help save patients, health insurers from unnecessary evaluation expenses

Heart disease remains the leading cause of death in men and women within the United States (http://ibn.fm/iTWKf), accounting for one out of every four deaths, and, as such, is fertile ground for research that is published regularly in professional periodicals such as the Journal of the American Heart Association (http://ibn.fm/xrAJK). The ailment is also the inspiration for a variety of business enterprises aiming to help the public reduce heart disease risks, and among those companies is health care technology company Zenosense, Inc. (OTCQB: ZENO), a co-owner of the United Kingdom’s MIDS Medical Limited (MML) and its innovative handheld MIDS technology, as implemented in the ongoing development of its MIDS Cardiac device.

MIDS Cardiac aims is to deliver true laboratory accuracy, performing high-sensitivity troponin tests in the emergency room or out in the field to better identify if a patient with chest pain or shortness of breath is experiencing a myocardial infarction. Troponin is a heart protein generally searched for by emergency room physicians as a quick indicator if damaged cardiac cells have entered the blood stream, and new age high-sensitivity troponin tests are delivering critical information to doctors more rapidly than before.

The majority of patients presenting themselves with chest pain or shortness of breath are ultimately found to not be experiencing acute heart attacks, but the critical concern associated with their symptoms can lead to unnecessary hospital admissions and tests that increase the medical expenses borne largely by patients and their insurance providers.

Best-practice diagnostics not only minimize the risk of unnecessary medical expenses; they pave the way for patients to receive the appropriate medical treatment for their conditions. The in-development MIDS device has particular importance in establishing the proper treatment of such events.

“Chest discomfort is one of the most commonly-encountered complaints in outpatient medicine, and represents a major diagnostic challenge as patients often present with a broad range of non-specific symptoms or signs,” Dr. James Januzzi Jr. of Massachusetts General Hospital wrote in a report on one heart diagnostics study (http://ibn.fm/GZ3kA).

Zenosense is developing the MIDS Cardiac device to help ER doctors rapidly conduct high-sensitivity troponin tests and also to make the technology portably available to ambulance first responders as they are treating patients in the first moments of an incident at a distance from the hospital. MIDS Cardiac aims to provide laboratory standard results within three minutes and additional cardiac biomarker testing within eight minutes utilizing a single pinprick of blood.

High-sensitivity troponin testing has been in clinical use in other parts of the world, including Europe, Canada and Australia, for over seven years, but the United States only approved the first such analyses last year (http://ibn.fm/l8bsK). As a result, no point of care tools are available to conduct true high-sensitivity testing, making the need for portable devices such as the MIDS product apparent. The technology is being developed to enable automated operation of the final device, suitable for use by minimally trained personnel, even in an ambulatory setting.

In July, the company posted quantitative testing results indicating that the MIDS technology had successfully detected a number of assay beads approximately four times lower than the maximum threshold required as suitable for a high-sensitivity troponin assay.

“The results of this second round of testing are quite extraordinary, as magnetic detection at this level for this application is unheard of,” Managing Director and Chief Scientific Officer Dr. Nasser Djennati stated in a news release (http://ibn.fm/aVNAE). “We can now move forward and apply the MIDS detection to established assay techniques used in conventional analyzers as we seek to deliver state-of-the-art laboratory standard, high sensitivity cardiac troponin testing at the Point of Care.”

Planning is now underway for the next key phase of development to test microfluidic detection on the revised electronics platform and to embody a high sensitivity assay on a test strip.

For more information, visit the company’s website at www.Zenosense.com

• Zenergy’s vision is helping businesses through responsible energy use and management
• The company focuses on significantly decreasing the carbon footprint in America
• Zenergy features its Zero Cost Program

Zenergy Brands, Inc. (OTC: ZNGY) specializes in lessening utility consumption. A business-to-business (B2B) enterprise, the company provides retail energy, energy conservation, smart controls and efficiency-based products and services. Its corporate vision is to enhance businesses by way of responsible energy use and management. The company is based in Dallas, Texas.

Zenergy serves commercial, industrial and municipal customers. It offers these customers the ability to decrease their utility consumption from 20 percent all the way up to 60 percent via its Zero Cost Program. The program is designed to help customers reduce electricity, natural gas and water consumption, as suited to their specific needs.

Zenergy Brands’ emphasis is on significantly lessening the carbon footprint in America. In addition, its focus is on substantially decreasing the demand on the national energy grid and on the nation’s water supply; the Zero Cost Program is an excellent means to this end.

For instance, with every Zero Cost Contract initiated, Zenergy performs an industry best practices analysis. It does so to ascertain what the environmental impact is per customer contract. It desires to help its customers realize their sustainability goals and lessen damaging carbon emissions by way of the Zero Cost Program.

The program enhances businesses by immediately decreasing energy consumption. It facilitates this through the use of smart controls, building automation, LED lighting solutions, refrigeration optimization, efficient water systems, EC motor controls, demand-side management and load factor correction (http://ibn.fm/Zx0tr).

Fundamentally, the Zero Cost Program is a financing mechanism. It allows the company’s customers to reduce utility consumption with no out-of-pocket cost. It achieves this via the implementation of proven conservation technologies. The program was developed based on an industry standard agreement known as a Managed Energy Services Agreement (MESA). With MESA, Zenergy Brands acts as a go-between for the customer and the utility. It develops, obtains financing for, installs and maintains energy efficiency measures and equipment at clients’ facilities (http://ibn.fm/1Ufjc).

The Zero Cost Program is finding increased acceptance in diverse markets. Recently, Zenergy Brands announced that it closed a Zero Cost contract with a Texas-based franchisee of a recognized fast food restaurant chain. In a recent news release, Zenergy Vice President of Business Development Jeff Bay-Andersen said, “We are excited about this partnership and hopeful that this deal marks the beginning of an upward trend whereby we can secure more Zero Cost contracts with other similar franchisees.” This deal is worth a total contract value of $393,969 (http://ibn.fm/ZCqU7).

Zenergy Brands continues to innovate in its efforts to help its customers drive down energy consumption. The company’s focus is wise energy usage and providing shareholders quality returns based on a broader adaption of its Zero Cost Program. Zenergy is at the forefront of cutting-edge solutions to efficient energy usage.

For more information, visit the company’s website at www.ZenergyBrands.com

• First medical cannabis producer in North America to meet rigorous standards of GMP certification, supplying cannabis flower and extracts
• Canadian federally-licensed cannabis cultivator, processor and distributor
• Q2 2018 revenue increased to $9.7 million, up 95.2 percent over second quarter of 2017
• Multinational distribution network makes Tilray medical cannabis available to patients in 11 countries on five continents
• Raised $163.6 million in a successful IPO in July 2018 and $55 million from leading institutional investors prior to IPO
• Agreements signed to supply medical cannabis via Canadian pharmacies and recreational cannabis to adult-use consumers in seven Canadian provinces and territories
• Received U.S. government approval to import cannabinoid study drug to UC San Diego for clinical trial for treatment of essential tremor, a neurological disorder

Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, continues to build an international footprint in the cannabis space with a long list of “firsts” in the cannabis industry. As one of only a few cannabis companies with a U.S. stock listing, Tilray’s stock has been a favorite of investors, soaring more than 10-fold since its initial public offering in July. Tilray’s diverse management team of industry leading experts includes PhD research scientists, master horticulturalists, engineers and patient advocates, in addition to backing by billionaire investor Peter Thiel.

Tilray’s aggressive pursuit of agreements to supply premium cannabis products to not only the Canadian market, which is poised to become the first G7 country to legalize recreational cannabis nationwide in October, but to any country that has legalized cannabis. Among its most recent announcements, the company has:

• Executed a non-binding letter of intent with IntelGenx Corp. to co-develop and commercialize oral film products infused with recreational and medical cannabis (http://ibn.fm/OAFLK)
• Received approval from the U.S. Drug Enforcement Administration (DEA) to import a medical cannabis supply drug for a clinical trial on essential tremor at the University of California San Diego Center for Medicinal Cannabis Research (http://ibn.fm/dXv4s)
• Regulatory permits approved for export to Germany of medical cannabis flower and full-spectrum medical cannabis oil for patient use (http://ibn.fm/BAgNU)
• Currently supplying products for several different clinical trials in partnership with universities, hospitals and governments in Australia and Canada (http://ibn.fm/gIv0T)
• Established wholly owned subsidiary High Park Company to produce and distribute a broad-based portfolio of cannabis brands and products in Canada; an investment totaling $100 million that’s expected to grow the company’s Canadian workforce to more than 500 in the next several years

In Deloitte’s 2018 cannabis report (http://ibn.fm/4vTb5), the research firm frames the total cannabis market in Canada as “significant” and one that has “spurred innovation, entrepreneurship and jobs.” Canada’s medical and recreational cannabis market is expected to generate $7.17 billion in total sales in 2019.

Brendan Kennedy, president and chief executive officer of Tilray, notes the company’s strong start to 2018 and offers insight to its future plans in a second quarter earnings report to stakeholders (http://ibn.fm/WNKql).

“Tilray is well-positioned to continue to pioneer the development of the global medical cannabis market and to become a leader in the adult-use cannabis market in Canada,” Kennedy states in the report. “In the second quarter, we generated significant revenue growth as a result of our global strategy, our multinational distribution network and our commitment to research, innovation, quality and operational excellence.”

Financial highlights in the report include an increase in revenue to $9.7 million, up 95.2 percent compared to the second quarter of 2017; a 97 percent increase in total kilogram equivalents sold compared to the prior year; and an average net selling price per gram increase from $6.20 to $6.38.

Business highlights in 2018 to date show Tilray’s successful IPO and funding received from institutional investors that brought $218.6 million to the company; signed agreements to supply cannabis to adult-use consumers in seven Canadian provinces and territories and signed strategic agreements with Sandoz Canada, a division of Novartis, to collaborate on the creation and sale of co-branded and co-developed non-combustible medical cannabis products. Agreements or LOIs were also signed with Shoppers Drug Mart Inc., Canada’s largest pharmacy chain, and Pharmasave, one of Canada’s leading independent pharmacy chains, to provide Tilray products once certain legal steps have been met.

Exports to Argentina, South Africa and the United Kingdom now make Tilray products available in 11 countries on five continents. The company also launched High Park Holdings Ltd., a wholly owned subsidiary formed to serve the pending adult-use market in Canada, in addition to the launch of the CANACA brand, which celebrates the historic moment in Canada as it becomes the first G7 nation to federally legalize cannabis for adult-use.

Tilray’s company culture promotes experience, precision, research and care for its customers and clients. Its precisely formulated products are cultivated to meet exacting patient needs and come in two primary forms – extracts and dried flower. Tilray’s product line centers on active ingredients and standardized, well-defined preparations with a focus on patient safety and efficacy. The company’s clinical research program is designed to evolve current scientific understanding of the therapeutic value and risks of cannabinoid-based medicines. Tilray’s flagship production facility is located in Nanaimo, Vancouver Island, British Columbia.

For more information, visit the company’s website at www.Tilray.com

• ChineseInvestors.com sees astounding 28,859 percent revenue growth in CBD product brands
• Company tapping into economic potential of huge ethnic Chinese population in China and North America
• Company delivers education and analysis in Chinese on all aspects of cryptocurrency production and trade

A financial information company dedicated to empowering Chinese-speaking investors and building on the market potential of cannabis-infused health and wellness products is announcing the expansion of its footprint in North America with the opening of offices in eastern Canada. ChineseInvestors.com, Inc. (OTCQB: CIIX) issued a news release on September 17 stating that it now has a sales and support office in Richmond, British Columbia, in addition to its headquarters in San Gabriel, California, and other corporate satellites in New York City and Shanghai.

The new British Columbia offices are located in the heart of Richmond’s busy financial district in the Pacific Business Centre, a prime location in close proximity to major Canadian banks, SkyTrain stations, shopping plazas and the neighboring Service Canada Centre, according to the news release (http://ibn.fm/fKGtp).

“With 54% of Richmond, British Columbia’s population representing individuals of Chinese ethnicity, we are in the optimal Canadian location to serve our target market,” CEO Warren Wang stated in the release, noting ChineseInvestors.com’s “long history of delivering quality, innovative subscription and educational services to Chinese globally.”

China’s citizens comprise the world’s largest national population — estimated this month to be at over 1.4 million people or 18.54 percent of the total planet’s population, according to the United Nations (http://ibn.fm/QVLdp). Ethnic Chinese people’s presence in North America mirrors their global anthropological status — they make up the largest subset of the diverse Asian American community (http://ibn.fm/ArsNy) and are collectively a potential economic engine.

ChineseInvestors.com is focused on delivering market analysis and education in the Chinese language to assist investors striving to participate in market activity. In November, the company launched a news and investment education portal covering strategies and opportunities to capitalize on the rising star of cryptocurrency and blockchain markets, including trading guidelines, market commentary and analysis. After the beginning of the new year, the company began producing a daily cryptocurrency video newscast in Chinese in conjunction with independent news agency Wall Street Multimedia.

ChineseInvestors.com’s fiscal year-end report adds that the company’s gross operating revenues experienced a 41 percent year-over-year increase primarily as a result of consumer product sales tied to its subsidiaries’ hemp brands. Its hemp oil and liquor products were the primary reason its sales grew from $1,308 the previous May to $377,719 this year — an astounding 28,859 percent increase. Revenues from the company’s cryptocurrency brands grew from $19,453 to $206,648 during the year (http://ibn.fm/VP0OL).

The company plans to establish a cryptocurrency ATM network with an online coin-to-coin exchange for Chinese cryptocurrency investors, and to dedicate more resources to marketing its hemp-based CBD products as the government regulatory climate continues to yield to popular clamor for greater legalization of hemp as an agricultural commodity. Eventually, ChineseInvestors.com expects to spin off its CBD division, ChineseHempOil.com, Inc. In the meantime, the company has set its sights on moving into more U.S. states, Toronto and Japan, Wang told MoneyTV (http://ibn.fm/CQTPf).

Wang said that he hopes the CBD spinoff will take place by year-end as part of a drive to list on the OTC or a national exchange such as Nasdaq in the coming months.

“We intend to continue to expand our consumer division by dedicating more resources to marketing hemp-based CBD products both domestically and in China,” Wang stated in the interview. “At the same time, we will continue to offer our core financial subscription services with a focus on increasing subscription revenues through targeted marketing of the Company’s new cryptocurrency subscription services and educational products.”

For more information, visit the company’s website at www.ChineseInvestors.com

• Marifil Mines presented promising results related to the availability of gold in the San Roque property in Argentina
• Samples were processed adhering to the strictest industry quality assurance standards
• Marifil Mines announced a financing initiative aimed at generating a cumulative amount of $1 million

Canada-based Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF) recently received the preliminary results for its diamond core drilling program at the Argentine San Roque property, indicating significant mineralization at the four holes that were tested, according to a company release (http://ibn.fm/sMXVb). The release also emphasizes Marifil Mines’ commitment to rigorous quality assurance and quality control at its San Roque property, located near the Atlantic coast in the Province of Rio Negro, Argentina.

Preliminary assay results for the company’s diamond core drilling program highlight the use of four HQ-size core holes totaling 846 meters (2,776 feet), with gold mineralization reported for all four holes. Currently, there are 112 holes at the property totaling 16,683 meters (54,734 feet). Each one of the holes intercepted some degree of mineralization, which is indicative of an extensive mineralization system. Some of the holes are below the grade cut-off level as presented by the company. In some instances, mineralization starts at the surface and continues to the bottom of the hole.

Marifil Mines is the project operator at San Roque. The property is held by Minas San Roque S.A., which is jointly owned by Marifil’s wholly owned subsidiary, Marifil Mines S.A. (51 percent), and NovaGold Resources Inc.’s (TSX: NG) wholly owned subsidiary, NovaGold Argentina Inc. (49 percent).

The company carried out an extensive, systematic quality assurance program at San Roque aimed primarily at maintaining the integrity and safety of the drill core samples. The samples were kept in a secure location and were shipped in tamper-proof bags for assaying at Alex Stewart Argentina S.A. (ASL) in Mendoza. The analysis was also carried out following rigorous quality standards.

All of the drill core samples’ analytical results were reviewed by an independent geochemist consultant. According to the review, the Marifil quality assurance program at San Roque conforms with the best industry practices, with only minor adjustments required to make it fully compliant, and assay results are within acceptable limits for accuracy and precision. Marifil Mines has already addressed the minor adjustments to be incorporated into the next drilling program, which were primarily to produce duplicate samples from the remaining half of the drill core instead of submitting a quarter of the corresponding core as Marifil did previously.

In addition to presenting the San Roque property results, Marifil has also made a financing announcement. As of September 13, the company has arranged a non-brokered private placement financing that consists of up to 10 million units, each one priced at $0.10. The gross proceeds are anticipated at $1 million.

Each individual unit consists of a Marifil Mines share and one share warrant. The warrant enables the owner of the share to acquire one additional share of the company at an individual price of $0.15. The period during which this acquisition can take place is two years from the closing of the current financing.

All of the securities to be issued are going to be the subject of a hold period that’s bound to expire in four months from a day after the closing of the financing. Several conditions will apply to the financing, including the receipt of all regulatory approvals.

Marifil Mines is dedicated to acquiring resource-rich properties in Argentina, with a primary focus on lithium, cobalt and gold exploration. In addition to the San Roque property, the company currently holds mining claims to 15,250 hectares (37,700 acres) of land in the Argentine Puna, within the famed ‘Lithium Triangle,’ where it has revived its lithium exploration program, which was halted in 2009. The company also owns the Las Aguilas property in central Argentina, which is currently the country’s largest known nickel/cobalt property.

For more information, visit the company’s website at www.MarifilMines.com

• Owner of two international U.S. patents and six patents issued by the People’s Republic of China, including three invention patents and three utility model patents
• Revenue for China’s solid waste recycling industry grew at a CAGR of 13.5 percent to an estimated $16.2 billion from 2014-2018
• Sustainable and eco-design recycling trends of industrial waste recycling creating value by extending a products’ life-cycles
• TMSR’s patented green technology allows industrial companies to extract valuable metal byproducts from solid industrial waste
• Global mining waste management market expected to reach 233.56 billion tons by 2022 at a CAGR of 6.1 percent from 2017-2022

TMSR Holding Company Limited (NASDAQ: TMSR), together with its subsidiaries, is providing a clear choice for companies producing industrial solid waste in China that are looking for a clean alternative to traditional waste disposal. Recognized as an industry leader in the research, development, production and sale of solid waste recycling systems and zero emissions process systems for the industrial and mining sectors in the People’s Republic of China, TMSR operates through its wholly owned business divisions: Shengrong Environmental and Wuhan HOST Coating Materials.

The solid waste recycling industry in China continues to grow, even after the Chinese government banned the import of 24 categories of recyclables and solid waste by the end of 2017. The country’s high demand for limited resources, rising concerns about the environment and urbanization are fueling the industry’s growth. Revenue for the solid waste recycling industry in China grew at an annualized rate of 13.5 percent from 2014-2018 to an estimated $16.2 billion, according to an industry report issued by IBISWorld (http://ibn.fm/fzCYM).

The global waste recycling market, which covers municipal solid waste, industrial non-hazardous waste, construction and demolition waste, plastic waste,and waste from electrical and electronic equipment, is also expanding and expected to generate $282.1 billion in 2018, according to a report by Frost & Sullivan (http://ibn.fm/nuweA).

TMSR subsidiary Shengrong Environmental designs, builds, sells and services customized solid waste recycling systems and equipment to tackle much of the waste produced by these industries. Shengrong’s patented equipment can process aluminum slag, copper mine tailings, iron mine tailings, red mud manganese tailings and molybdenum tailings, among many others. Unlike traditional chemical-based recovery methods, the company extracts resalable metals from the waste without generating any pollution. The residues are processed to manufacture high-quality construction materials, turning polluted solid waste into valuable industrial materials with zero discharge (http://ibn.fm/wQvZJ).

Trends of industrial waste recycling include innovative business models and disruptive technologies including “green technologies” such as those offered by TMSR. By supporting principles of sustainability, TMSR provides end users in the solid waste recycling markets a clean alternative that significantly reduces solid waste discharge into the environment, reducing energy use and pollution while creating value for businesses and extending products’ life-cycles.

For more information, visit the company’s website at www.TMSRHolding.com

• Biotech company is focused on becoming a worldwide leader in R&D and sale of hemp-derived, CBD-based nutraceuticals, pharmaceuticals and dietary supplements
• ETST is developing three new CBD formulas in Canada under a provisory patent; it is also clinical testing its Hygee medical device for detecting sexually transmitted diseases in women
• With its Form 10 Registration Statement filing now effective, ETST will begin reporting annual, quarterly and periodic financial statements

Earth Science Tech, Inc. (OTCQB: ETST) anticipates that its uplisting to the OTCQB Venture Market will enable it to reach global recognition and increase liquidity as a leader in the hemp-based CBD space in several fields, such as cannabinoid products. It also develops innovative medical devices designed for multi-national marketing (http://ibn.fm/IArhk).

The Florida-based company seeks to raise its recognition level and perform more R&D for the CBD industry. ETST manufactures, markets and distributes its own cannabinoid products, including capsules and oils. It is a leader in the medical cannabis markets, with its products available at retail health food stores and e-liquid smoke shops.

“Historically, up-listing to the OTCQB and being fully reporting has resulted in greater liquidity and awareness,” Nickolas S. Tabraue, president, director and chairman of ETST, stated in a news release (http://ibn.fm/kFLuV). “We are committed to the higher level of corporate and financial disclosures required as an OTCQB fully reporting company, demonstrating our commitment to our loyal shareholders.”

In Canada, it is testing three new CBD IP formulations. It is also clinical testing its Hygee MSN-2 medical device for detection of sexually transmitted infections (STIs) in women at Québec’s Clinique Santé Amitié (http://ibn.fm/BGONO).

It is developing two new products in Brazil in a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division Bionatus Botanical Laboratories, Inc. In the U.S., it is conducting studies with the University of Central Oklahoma on the impact of high grade full spectrum CBD on immune cells and breast cancer (http://ibn.fm/WvDDW).

ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.

For more information, visit the company’s website at www.EarthScienceTech.com